PROMIS NEUROSCIENCES INC (PMN) Stock News

NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD

0.9865 +0.08 (+8.89%)

After market: 0.9425 -0.04 (-4.46%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PMN Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill - Mentions: HIT MEDP CDLX REPL ...

News Image

Which stocks are experiencing notable movement on Tuesday?

5 days ago - By: Chartmill - Mentions: KSS KIRK MEDP CDLX ...

News Image

Let's have a look at the top gainers and losers in the middle of the day of today's session.

5 days ago - By: Benzinga - Mentions: PAPL AIRE ABVX TLX ...

Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

5 days ago - By: Chartmill - Mentions: KSS AEHR MEDP REPL ...

News Image

Gapping stocks in Tuesday's session

5 days ago - By: Chartmill - Mentions: MEDP REPL PGEN HTOO ...

News Image

Which stocks are moving before the opening bell on Tuesday?

5 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

5 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

5 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

6 days ago - By: Chartmill - Mentions: CLRO OPEN RDHL BNED ...

News Image

Which stocks are experiencing notable movement on Monday?

6 days ago - By: Chartmill - Mentions: PLUG OPEN NCNA QS ...

News Image

Monday's session: most active stocks

6 days ago - By: Chartmill - Mentions: MEIP ATNF VRAR TRON ...

News Image

These stocks have an unusual volume in today's session

6 days ago - By: Benzinga - Mentions: EVO DPZ BNED OP ...

Nasdaq Surges Over 100 Points; Domino's Shares Fall After Q2 Results

6 days ago - By: Chartmill - Mentions: BRKR OPEN SRPT BULL ...

News Image

Get insights into the top gainers and losers of Monday's pre-market session.

6 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

a month ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

4 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

4 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

4 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

4 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

5 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

5 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

5 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

5 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

5 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

6 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

6 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Issues Letter to Shareholders

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Issues Letter to Shareholders

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease

8 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

9 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

9 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

9 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

9 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference